Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Study ID
SPOC-2011-001

Cancer Related
Yes

Healthy Volunteers
No

Study Sites

  • Clements University Hospital
  • UT Southwestern Ambulatory Services
  • Zale Lipshy University Hospital
  • Parkland Health & Hospital System

Contact
Isabel Villalobos
214/648-7010
isabel.villalobos@utsouthwestern.edu

Principal Investigator
Jayanthi Lea

Official Title

Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma

Brief Overview


The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus
ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma.
In addition, researchers would like to determine if the drugs are most effective together or
if fenretinide (4-HPR/LXS) is most effective alone.

Summary


In this study, an initial Phase I component of six patients will be conducted to monitor for
potential toxicities as this wil be the initial adult experience of fenretinide (4-HPR)
given together with ketoconazole

Participant Eligibility


Inclusion Criteria:

- Recurrent epithelial ovarian cancer or primary peritoneal carcinoma that can be
platinum sensitive or platinum resistant

- SWOG Performance Status 0-2

- Previously received a platinum and paclitaxel containing regimen

- Projected Life Expectancy of at least 3 months

- Adequate bone marrow function

- Adequate organ function

- Must have received at least 1 prior salvage regimen for recurrent ovarian cancer

- Recovery from acute toxicities from surgery, radiation or chemotherapy

- At least 3 weeks from last therapy

Exclusion Criteria:

- Prior fenretinide oral capsule use allowed. If prior IV fenretinide use, must contact
study chair for eligibility

- Second malignancy within last 5 years

- Use of concomitant antioxidants, such as vitamin C or E

- Untreated or symptomatic brain metastases

- History of hypertriglyceride levels > 200 mg/dl; triglyceride levels < 200 and
receiving treatment are okay.

- Use of certain medications is prohibited - contact study coordinator for information